Agreement - January 20, 2021
Recipharm signs manufacturing agreement with Enzymatica
Recipharm and Enzymatica have signed a broadened contract for the manufacture of ColdZyme. The agreement will involve an additional Recipharm production site in Pianezza, Italy, to support Enzymatica in increasing production volumes of ColdZyme to meet growing global demand. Both the facilities in Parets, Spain, and Pianezza, Italy, will be making additional investments to accommodate […]
Contract Services - January 18, 2021
Cobra Biologics announces major facility expansion in US and Europe
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase augmentation of its plasmid DNA services as a continuation of its Gene Therapy services’ expansion project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ (High Quality) DNA manufacturing capacity alongside new clinical and commercial GMP […]
Contract Services - December 15, 2020
Recipharm invests USD 2.5 million in clinical GMP capacity
Recipharm, has announced an investment and capacity expansion at its facility in Israel. This investment will support customers’ growing demand for cGMP clinical supply of active pharma ingredients (API) and intermediates and is part of an integrated plan to enhance Recipharm’s offering in drug substances services, the company states. Fully operative by the end of […]
Business article - October 8, 2020
Brick by brick – The Recipharm journey
2020 is the year Recipharm celebrates 25 years of CDMO business. Chief Executive Officer and co-founder, Thomas Eldered looks back upon milestones, crucial turning points and the company’s goal of simplifying a product’s journey to market. The journey of Recipharm began in 1995 with the buyout of a solid dose facility in Stockholm, performed by […]
Contract Services - August 18, 2020
Cobra Biologics completes production of master cell banks for CombiGene
Cobra Biologics and CombiGene have announced that Cobra has produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. Critical to assuring ‘life time’ supply of therapeutic, this represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal […]
Contract Services - August 18, 2014
Cobra Biologics expands production facility
The contract manufacturer Cobra Biologics are hiring new employees to the company’s production facility in Matfors in northern Sweden. In four years, the company has doubled its staff and in the spring of 2014 half a dozen employees were recruited. The company could have around 50 staff members in the fall, says local manager Lars […]
